Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC By Ogkologos - August 21, 2025 520 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-426 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Enhertu Improves Survival for Metastatic “HER2-Low” Breast Cancer July 5, 2022 Study Shows Music Eases Pain and Other Symptoms for Patients Undergoing... June 6, 2019 Two Drugs Work Together to Block ‘Master Regulator’ of Breast, Other... September 4, 2018 Cancer in My Community: Working to Eliminate the Stigma of Cancer... September 14, 2021 Load more HOT NEWS Home Is Where the Heart Is EMA Recommends Extension of Therapeutic Indications for Durvalumab to Patients with... Breast-Cancer Mom Is Living On 84 Pence As She Fights For... What to Know About Exercising During Prostate Cancer: An Expert Q&A
